SCHEMBL6020181

SCHEMBL6020181

CC(C)(C)OC(=O)NC(Cc1ccc(O)cc1)C(=O)NCC#N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSS P25774 18/20 1.00
CTSK P43235 15/20 1.00
CTSB P07858 4/20 0.82
CTSL P07711 3/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14599153 0.90 CTSS (1.00) CTSSCTSKCTSBCTSL
SCHEMBL6020639 0.90 CTSS (1.00) CTSSCTSKCTSBCTSL
SCHEMBL6021008 0.90 CTSS (0.81) CTSSCTSKCTSBCTSL
SCHEMBL6020388 0.88 CTSS (0.78) CTSSCTSKCTSBCTSL
SCHEMBL2928795 0.88 CTSS (0.78) CTSSCTSKCTSBCTSL
SCHEMBL31181953 0.87 CTSS (0.77) CTSSCTSKCTSBCTSL
SCHEMBL2929067 0.85 CTSS (0.74) CTSSCTSKCTSBCTSL
SCHEMBL6021014 0.85 CTSS (0.73) CTSSCTSKCTSBCTSL
SCHEMBL9053570 0.84 CTSS (0.73) CTSSCTSKCTSBCTSL
SCHEMBL6020218 0.84 CTSS (0.73) CTSSCTSKCTSBCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 CTSS 2720/4885CTSK 2529/4885CTSB 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.